A shareholder class action against BHP over the 2015 Fundao dam collapse in Brazil has won a bid to add an extra three weeks to a six-week hearing to account for any evidentiary surprises.
Cipla is opposing the extension of Novo Nordisk’s patent for its Victoza weight loss and diabetes drug, arguing extensions can only be granted for active ingredients and not entire formulations.
The Commonwealth has argued that a long-running dispute involving drug makers Otsuka, Bristol-Myers Squibb and Generic Health should be put on ice until the High Court rules in a separate matter.
Distribution company Metcash has lost its bid to overturn a decision that found it had to provide employees with a 12-hour break between shifts irrespective of whether the work was ordinary or overtime hours.
Medibank is seeking to shield from a shareholder class action an “irrelevant” post-incident report by Deloitte into its massive October 2022 data breach.
The judge overseeing a $180.4 million settlement in a stolen wages class action has railed against Shine Lawyers’ $10 million bill for the costs of registration, saying “something has gone seriously wrong”.
United Petroleum will not face cross-claims by franchisees, with a judge calling the bid “a very colourable application” to create overlap with a class action in the Supreme Court.
ASIC has won its case against insurer HCF Life over a pre-existing condition term that was likely to mislead the public, but failed to convince the court that it was an unfair contract term.
AstraZeneca has brought court proceedings to block Australian drug maker Pharmacor from making a generic version of its heart attack drug Brilinta.
Santos’ plan to reach net zero greenhouse gas emissions by 2040 was “little more than a series of speculations”, a shareholder group has said on the first day of trial in a landmark greenwashing case.